The U.S. Food and Drug Administration wants to fast-track its review of psilocybin and methylone treatments.
The FDA is fast tracking its review of two psychedelic drugs for mental health treatments.
For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those ...
The grieving family of a mum who overdosed was told by her drug dealer 'I still need to be paid'. The Exeter mum was 'loved ...
Experimental therapies with radically different approaches are stirring a wave of optimism that survival rates could ...
“John said that I played ‘Season of the Witch’ for seven hours straight, all night and into the dawn,” he reveals. “I didn't ...
The move will bring enormous tax benefits to medical marijuana producers and may speed research into its effects, experts say ...
Eli Lilly remains well-positioned in the obesity treatment market despite early script underperformance of Foundayo. Read ...
The investigation into Sheena Bora's murder, and, later, the case, leans heavily on the half-burnt body found in rural ...
The federal rescheduling of marijuana announced by the Justice Department on Thursday doesn’t change how the Supreme Court ...
The song was recorded when she was three months pregnant with their daughter. The relationship came to an end in the months ...
Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results